Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Localized shortages of Nucynta® products reported

    by
    • Optum Workers' Comp
    | Feb 05, 2018
    Tag Icon
    Opioids
    Following the devastation and power outages in Puerto Rico from Hurricane Maria, Depomed issued a press release indicating there may be temporary delays in the packaging and delivery of Nucynta® ER (tapentadol extended-release). Certain dosage strengths are being manufactured by the company’s third-party partner located on the island and those dosages would be potentially affected. The company reported that it did not expect any disruption to the supply of the immediate-release (IR) formulation of Nucynta.


  • New drug therapy approvals in 2017

    by
    • Optum Workers' Comp
    | Feb 01, 2018
    Tag Icon
    The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has published their annual report, Advancing Health through Innovation: New Drug Approvals and Other Drug Therapy Advances of 2017. This report not only summarizes the approval of 46 new medications in 2017, it also provides information on the CDER’s role in supporting the FDA’s efforts to endorse innovation, efficiently execute the review and approval of new medications while maintaining patient safety, and improve various treatments for patients


  • Primus announces recall of Limbrel®

    by
    • Optum Workers' Comp
    | Jan 31, 2018
    Tag Icon
    recall
    In an effort to cooperate with the U.S. Food and Drug Administration’s (FDA) request to recall Limbrel, Primus Pharmaceuticals announced it is now voluntarily recalling all unexpired lots of this prescription medical food. Limbrel is used to manage the metabolic processes associated with osteoarthritis.


  • A change in federal policy on marijuana

    by
    • Optum Workers' Comp
    | Jan 30, 2018
    Tag Icon
    Medical Marijuana
    Earlier this month United States Attorney General Jeff Sessions issued a memorandum to all Department of Justice (DOJ) United States Attorneys that rescinded previous memoranda directed specifically at the enforcement of existing federal laws and prosecutorial discretion concerning marijuana. The memorandum is effective immediately. This memorandum initiates a policy change from the previous DOJ policy, which may impact marijuana enforcement at the Federal and State level. Despite this federal policy change, our guiding philosophy on the use of medical marijuana for the treatment of pain has not changed.